F
6.81
0.77 (12.75%)
| 前收盘价格 | 6.04 |
| 收盘价格 | 6.02 |
| 成交量 | 958,041 |
| 平均成交量 (3个月) | 512,254 |
| 市值 | 64,131,780 |
| 价格/销量 (P/S) | 10.25 |
| 股市价格/股市净资产 (P/B) | 0.770 |
| 52周波幅 | |
| 利润日期 | 14 Nov 2025 |
| 营业利益率 (TTM) | -981.18% |
| 稀释每股收益 (EPS TTM) | -9.42 |
| 总债务/股东权益 (D/E MRQ) | 32.52% |
| 流动比率 (MRQ) | 9.41 |
| 营业现金流 (OCF TTM) | -62.63 M |
| 杠杆自由现金流 (LFCF TTM) | -61.34 M |
| 资产报酬率 (ROA TTM) | -29.82% |
| 股东权益报酬率 (ROE TTM) | -60.22% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Korro Bio, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
1.1
| 分析师共识 | 1.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 0.5 |
| 平均 | 1.13 |
|
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 6.18% |
| 机构持股比例 | 104.23% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Tri Locum Partners Lp | 30 Sep 2025 | 337,764 |
| 72 Investment Holdings, Llc | 30 Sep 2025 | 276,831 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 93.00 (Clear Street, 1,265.64%) | 购买 |
| 中 | 8.00 (17.47%) | |
| 低 | 7.00 (Chardan Capital, 2.79%) | 保留 |
| 平均值 | 36.00 (428.63%) | |
| 总计 | 1 购买, 2 保留 | |
| 平均价格@调整类型 | 17.97 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Chardan Capital | 13 Nov 2025 | 7.00 (2.79%) | 保留 | 6.50 |
| RBC Capital | 13 Nov 2025 | 8.00 (17.47%) | 保留 | 6.50 |
| Clear Street | 31 Oct 2025 | 93.00 (1,265.64%) | 购买 | 40.91 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合